US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Follicum AB reports that all patients have completed treatment with FOL-005 in the Phase II study against hair loss

Follicum AB today announced that all patients in the ongoing Phase IIa study with FOL-005 for the treatment of hair loss have completed treatment and made their final visits to the clinic. The study examines the safety and treatment effect of different doses of the drug candidate FOL-005  in just over 200 male patients. Top line results are expected to be presented during spring 2021.The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. The patients themselves have applied one of three different

All patients included in Follicum's Phase II study with FOL-005 for stimulation of hair growth

Follicum AB today announced that all patients have been included in the company's ongoing Phase IIa clinical study with its lead drug candidate FOL-005. The study involves more than 200 male patients with hair loss who are being treated with a newly developed topical formulation of FOL-005. No noteworthy adverse reactions have been reported so far and to date none of the patients included have discontinued their participation in the study. The results are expected to be presented in spring 2021.The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy

More than 50% of patients enrolled in Follicum's Phase II study of FOL-005 for stimulation of hair growth

Follicum AB ("Follicum" or the "company") today announced that more than 50% of the patients have  been recruited in the ongoing, clinical phase IIa study with FOL-005. The study involves 200 male patients with hair loss who are treated daily for four months with a newly developed topical formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin, at proDERM in Hamburg and at CentroDerm® in Wuppertal.Two previous clinical studies have shown that intradermal injections of FOL-005 are an effective and safe

Follicum AB reports top-line data from First-in-Man Scalp Study with FOL-005 against hair loss

Follicum AB ("Follicum" or "Company"), a biotech company that develops new drugs in two areas, hair loss and diabetes, today reports top-line data from the first phase IIa study with FOL-005 for the treatment of hair loss on scalp in patients. The phase IIa study examined the safety and therapeutic effect of different doses of the drug candidate FOL-005, administered as injections into the scalp 3 times per week. The results confirmed that the treatment was safe with minimal side effects reported. Furthermore, increased hair growth was measured at the highest dose. Follicum will now follow up

Follicum AB on schedule to present top-line results from the phase IIa study with FOL-005 for hair growth at the end of October 2018

Follicum AB ("Follicum") reported on August 28, 2018 that all patients in the phase IIa study with FOL-005 for hair growth had completed their treatment. Today Follicum, in according with the company's communicated time lines, announced it expects to present top-line results from the Phase IIa study by the end of October 2018.Follicum's Phase IIa study has been conducted at the CRC in Berlin and bioskin, Hamburg, Germany. The Phase IIa study aims to investigate the safety and therapeutic effect of four different doses of FOL-005 and placebo, administered as injections into the patient’s

There are no items matching the current filter
There are no more items matching the current filter
Back to top